Harada KI - Search Results

1

Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.

Takai R, Funakoshi Y, Suto H, Nagatani Y, Imamura Y, Toyoda M, Yakushijin K, Kiyota N, Harada KI, Yamashita K, Kakeji Y, Minami H. Takai R, et al. Among authors: harada ki. Anticancer Res. 2021 Feb;41(2):1021-1026. doi: 10.21873/anticanres.14857. Anticancer Res. 2021. PMID: 33517310

2

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.

Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H. Funakoshi Y, et al. J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. J Infect Chemother. 2022. PMID: 35090826 Free PMC article.

3

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.

Tomisaki I, Harada M, Sakano S, Terado M, Hamasuna R, Harada S, Matsumoto H, Akasaka S, Nagata Y, Minato A, Harada KI, Fujimoto N. Tomisaki I, et al. Among authors: harada ki, harada m, harada s. Anticancer Res. 2023 Jan;43(1):269-274. doi: 10.21873/anticanres.16159. Anticancer Res. 2023. PMID: 36585166

4

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.

Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, Miyamoto H. Fujimoto N, et al. Anticancer Res. 2023 Sep;43(9):3841-3847. doi: 10.21873/anticanres.16571. Anticancer Res. 2023. PMID: 37648316 Review.

5

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.

Minato A, Kimuro R, Ohno D, Tanigawa K, Kuretake K, Matsukawa T, Takaba T, Jojima K, Harada M, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N, Miyamoto H. Minato A, et al. Anticancer Res. 2023 Sep;43(9):4055-4060. doi: 10.21873/anticanres.16594. Anticancer Res. 2023. PMID: 37648337

6

Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.

Furubayashi N, Minato A, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Harada K, Kuroiwa K, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Anticancer Res. 2024 Apr;44(4):1675-1681. doi: 10.21873/anticanres.16966. Anticancer Res. 2024. PMID: 38537962

7

Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.

Ueki H, Hinata N, Kitagawa K, Hara T, Terakawa T, Furukawa J, Harada K, Nakano Y, Komatsu M, Fujisawa M, Shirakawa T. Ueki H, et al. Clin Transl Oncol. 2022 Mar;24(3):568-577. doi: 10.1007/s12094-021-02717-3. Epub 2021 Oct 23. Clin Transl Oncol. 2022. PMID: 34687441

8

Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.

Bando Y, Hinata N, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Bando Y, et al. Among authors: harada ki. Med Oncol. 2017 Aug 17;34(9):163. doi: 10.1007/s12032-017-1024-0. Med Oncol. 2017. PMID: 28819719 Clinical Trial.

9

The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinoma.

Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Teishima J, et al. Among authors: harada ki. Oncol Lett. 2023 Sep 20;26(5):470. doi: 10.3892/ol.2023.14057. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37809051 Free PMC article.

10

Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.

Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Teishima J, et al. Among authors: harada ki. Can Urol Assoc J. 2024 Jan 30. doi: 10.5489/cuaj.8548. Online ahead of print. Can Urol Assoc J. 2024. PMID: 38319607 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page